Literature DB >> 11436421

Cidofovir in the treatment of HPV-associated lesions.

R Snoeck1, G Andrei, E De Clercq.   

Abstract

The acyclic nucleoside phosphonate cidofovir (CDV) has proved efficacious in the treatment of different clinical manifestations of HPV-induced epithelial cell proliferation. Local intratumor injections of CDV in an immunocompetent patient with hypopharyngeal/esophageal papillomatous lesions, PCR-positive for HPV types 16 and 18, resulted in a complete regression of the tumor. Similarly, CDV, injected locally in patients with recurrent respiratory papillomatosis resulted in complete disappearance or partial remission of the lesions. Recently, a child with disseminated respiratory papillomatosis was treated with systemic (intravenous) CDV, resulting in stabilization of the disease. In addition, CDV topical gel has been successfully used for the treatment of severe, relapsing anogenital HPV lesions and cervical intraepithelial neoplasia (CIN) grade III. In vitro, treatment of HPV-positive cells (compared to normal primary human keratinocytes) with CDV has resulted in a concentration- and time-dependent inhibition of cell proliferation. Different parameters of apoptosis, i.e., (i) induction of CPP32 (caspase-3) protease activity, (ii) translocation of phosphatidylserine (PS) from the inner part of the plasma membrane to the outer layer, (iii) disintegration of the nuclear matrix protein (NMP), (iv) DNA fragmentation, (v) number of cells in apoptotic phase following cell cycle analysis, showed that the mechanism of cell death following treatment with CDV is based on apoptosis. Induction of apoptosis in HPV-positive cells by CDV was associated with accumulation of the tumor suppressor proteins p53 and pRb and the cyclin-dependent kinase inhibitor p21/WAF-1. In conclusion, CDV has great potential in the treatment of severe HPV-induced proliferative lesions, either laryngeal, esophageal/pharyngeal or genital. As CDV has proved able to induce apoptosis, in a time- and concentration-dependent manner, in a number of HPV-positive cell lines, the regression of papillomatous tumors observed with CDV in patients, may be due, at least in part, to the induction of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11436421

Source DB:  PubMed          Journal:  Verh K Acad Geneeskd Belg        ISSN: 0302-6469


  9 in total

1.  Intralesional Cidofovir application in recurrent laryngeal papillomatosis.

Authors:  Annett Pudszuhn; Cornelia Welzel; Marc Bloching; Kerstin Neumann
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-10-13       Impact factor: 2.503

2.  Formulation of cidofovir improves the anti-papillomaviral activity of topical treatments in the CRPV/rabbit model.

Authors:  Neil D Christensen; Nancy M Cladel; Jiafen Hu; Karla K Balogh
Journal:  Antiviral Res       Date:  2014-06-16       Impact factor: 5.970

3.  Surgical procedures for voice restoration.

Authors:  Tadeus Nawka; Werner Hosemann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

Review 4.  New molecular targets against cervical cancer.

Authors:  Alfonso Duenas-Gonzalez; Alberto Serrano-Olvera; Lucely Cetina; Jaime Coronel
Journal:  Int J Womens Health       Date:  2014-12-05

5.  Efficacy of commercially available biological agents for the topical treatment of cervical intraepithelial neoplasia: a systematic review.

Authors:  Alex Baleka Mutombo; Cindy Simoens; Rahma Tozin; Johannes Bogers; Jean-Pierre Van Geertruyden; Yves Jacquemyn
Journal:  Syst Rev       Date:  2019-06-07

6.  Reduced tumorigenicity and pathogenicity of cervical carcinoma SiHa cells selected for resistance to cidofovir.

Authors:  Tim De Schutter; Graciela Andrei; Dimitri Topalis; Sophie Duraffour; Tania Mitera; Joost van den Oord; Patrick Matthys; Robert Snoeck
Journal:  Mol Cancer       Date:  2013-12-10       Impact factor: 27.401

Review 7.  Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.

Authors:  Maryam Dadar; Sandip Chakraborty; Kuldeep Dhama; Minakshi Prasad; Rekha Khandia; Sameer Hassan; Ashok Munjal; Ruchi Tiwari; Kumaragurubaran Karthik; Deepak Kumar; Hafiz M N Iqbal; Wanpen Chaicumpa
Journal:  Front Immunol       Date:  2018-11-12       Impact factor: 7.561

8.  Antiviral Drugs for EBV.

Authors:  Joseph S Pagano; Christopher B Whitehurst; Graciela Andrei
Journal:  Cancers (Basel)       Date:  2018-06-13       Impact factor: 6.639

Review 9.  Cidofovir in the treatment of poxvirus infections.

Authors:  Erik De Clercq
Journal:  Antiviral Res       Date:  2002-07       Impact factor: 10.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.